Mr. Thomas Smeenk reports

HEMOSTEMIX CLOSES PRIVATE PLACEMENT OF USD $336,500 AT $0.295 PER SHARE

Per the company's Feb. 4, 2025, news release, Hemostemix Inc. has closed the previously announced $336,500 (U.S.) non-brokered private placement, issuing 1,634,466 common shares at 29.5 Canadian cents each to CytoImmune Therapeutics LLC, following the approval of the TSX Venture Exchange, in keeping with its guidance as announced on Jan. 9, 2025.

Per Policy 4.1, CytoImmune Therapeutics is arm's length to the company and is not a related party to the company at the time of disclosure.

The use of proceeds will be allocated to general working capital purposes, including business development activities.

The company confirms that there is no material fact or material change about the company that has not been generally disclosed.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in nine peer-reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 60 per cent in the CLTI patient population, the University of British Columbia and University of Toronto reported to the 41st meeting of vascular surgeons: 0-per-cent mortality, cessation of pain, wound healing in 83 per cent of patients followed for up to 4.5 years, as a midpoint result.

We seek Safe Harbor.